Evidence map›Paper›PMID 35658587›Full record

ArticleExperimental biology and medicine (Maywood, N.J.)2022

Apigeninidin-enriched

Solomon E Owumi, Moses T Otunla, Uche O Arunsi, Adegboyega K Oyelere

Open access · greenAbstract read
In one paragraph

Article in Experimental biology and medicine (Maywood, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
5.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. The Hydrophobic Extract ofMolecules (Basel, Switzerland) · 2023
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 3 countries.

Solomon E OwumiCancer Research and Molecular Biology Laboratories, NB 302, Department of Biochemistry, Faculty of Basic Medical Sciences, University of Ibadan, Ibadan 200005, Nigeria.ORCID 0000-0002-4973-0376
Moses T OtunlaCancer Research and Molecular Biology Laboratories, NB 302, Department of Biochemistry, Faculty of Basic Medical Sciences, University of Ibadan, Ibadan 200005, Nigeria.
Uche O ArunsiDepartment of Cancer Immunology and Biotechnology, School of Medicine, University of Nottingham, Nottingham NG7 2RD, UK.
Adegboyega K OyelereSchool of Chemistry & Biochemistry, Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA 30332-0400, USA.
University of Ibadan · NGGeorgia Institute of Technology · USUniversity of Nottingham · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We examined the protective effect of the apigeninidin (API)-enriched fraction from

Indexed as

Aflatoxin B1AnthocyaninsApigeninSorghumAnimalsAntioxidantsCaspase 9CytokinesFollicle Stimulating HormoneHypothalamusMaleOxidative StressPhytoalexinsPlant ExtractsProlactinRatsAflatoxin B1AnthocyaninsAntioxidantsApigeninapigeninidinCaspase 9CytokinesFollicle Stimulating HormonePhytoalexinsPlant ExtractsProlactinTestosteroneAflatoxin B1antioxidant activityhypothalamic–pituitary–gonadal axismale reproductive toxicityoxidative–inflammatory biomarkersSorghum bicolor

Identifiers

PMID35658587
PMCPMC9442456
OpenAlexW4281836626

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.